Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Marinus Pharma (NASDAQ:MRNS) and maintained a $28 price target.
September 21, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Marinus Pharma and maintained a $28 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Marinus Pharma. The maintained price target of $28 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100